Anthrax as a potential biological warfare agent

Archives of Internal Medicine

Volumn 158, Issue 5, 1998, Pages 429-434

  Pile, James C ^a   Malone, John D ^a   Eitzen, Edward M ^b   Friedlander, Arthur M ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANTHRAX; BIOLOGICAL WARFARE; HISTORY; HUMAN; MICROBIOLOGY; PATHOPHYSIOLOGY; REVIEW; VACCINATION;

ANIMALS; ANTHRAX; BIOLOGICAL WARFARE; HISTORY, 19TH CENTURY; HISTORY, ANCIENT; HISTORY, MEDIEVAL; HUMANS; VACCINATION;

EID: 0032498726     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.5.429     Document Type: Review

References (67)

1. Dirckx JH. Virgil on anthrax. Am J Dermatopathol. 1981;3:191-195.
2. Turnbull PCB. Bacillus. In: Baron S, ed. Medical Microbiology. 3rd ed. New York, NY: Churchill Livingstone Inc; 1991:249-262.
3. Wool disinfection and anthrax: a year's working of the model station. Lancet. December 16, 1922: 1295-1296.
4. Eurich FW. The history of anthrax in the wool industry of Bradford, and of its control. Lancet. January 2, 1926:57-58.
5. Tigertt WD. Anthrax: William Smith Greenfield, MD, FRCP, professor superintendent, the Brown Animal Sanatory Institution (1878-81) - concerning the priority due to him for the production of the first vaccine against anthrax. J Hyg (Lond). 1980;85:415-420.
6. Kaufmann AF. Observations on the ocurrence of anthrax as related to soil type and rainfall. Salisbury Med Bull Suppl. 1990;68:16-17.
7. De Vos V, Bryden HB. Anthrax in the Kruger National Park: temporal and spatial patterns of disease occurrence. Salisbury Med Bull Suppl. 1996; 87:26-30.
8. Brachman PS, Friedlander AM. Anthrax. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994: 729-739.
9. Anthrax control and research, with special reference to national programme development in Africa: memorandum from a WHO meeting. Bull World Health Organ. 1994;72:13-22.
10. Glassman HN. World incidence of anthrax in man. Public Health Rep. 1958;73:22-24.
11. Centers for Disease Control and Prevention. Summary of notifiable diseases, 1945-1994. MMWR Morb Mortal Wkly Rep. 1994;43:70-78.
12. Whitford HW. Incidence of anthrax in the USA: 1945-1988. Salisbury Med Bull Suppl. 1990;68: 5-7.
13. Walker DH, Yampolskaya O, Grinberg LM. Death at Sverdlovsk: what have we learned? Am J Pathol. 1994;144:1135-1141.
14. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 1993;90:2291-2294.
15. Davies JCA. A major epidemic of anthrax in Zimbabwe, part I. Cent Afr J Med. 1982;28:291-298.
16. Davies JCA. A major epidemic of anthrax in Zimbabwe, part II. Cent Afr J Med. 1983;29:8-12.
17. Davies JCA. A major epidemic of anthrax in Zimbabwe, part III. Cent Afr J Med. 1985;31:176-179.
18. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266:1202-1208.
19. Wade N. Death at Sverdlovsk: a critical diagnosis. Science. 1980;209:1501-1502.
20. Cogne R, Stares NE, Jones MN, Bowen JE, Turnbull PCB, Boeufgras JM. Identification of Bacillus anthracis using the 50CHB system. Salisbury Med Bull Suppl. 1996;87:34-35.
21. The aerobic gram-positive bacilli. In: Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC, eds. Color Atlas and Textbook of Diagnostic Microbiology. 4th ed. Philadelphia, Pa: JB Lippincott; 1992:467-518.
22. Smith H, Keppie J. Observations on experimental anthrax: demonstration of a specific lethal factor produced in vivo by Bacillus anthracis. Nature. 1954;173:869-870.
23. Stanley JL, Smith H. Purification of factor I and recognition of a third factor of the anthrax toxin. J Gen Microbiol. 1961;26:49-66.
24. Beall FA, Taylor MJ, Thorne CB. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol. 1962;83:1274-1280.
25. Lincoln RE, Fish DC. Anthrax toxin. In: Montie TC, Kadis S, Ajl SJ, eds. Microbial Toxins, Volume III: Bacterial Protein Toxins. New York, NY: Academic Press; 1970:361-414.
26. Leppla SH, Friedlander AM, Singh Y, Cora EM, Bhatnagar R. A model for anthrax toxic action at the cellular level. Salisbury Med Bull Suppl. 1990; 68:41-43.
27. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Pros Natl Acad Sci U S A. 1982;79:3162-3166.
28. O'Brien J, Friedlander A, Dreier T, Ezzell J, Leppla S. Effects of anthrax toxin components on human neutrophils. Infect Immunol. 1985;47:306-310.
29. Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Natl Acad Sci U S A. 1993;90:10198-10201.
30. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through acid-dependent process. J Biol Chem. 1986;261:7123-7126.
31. Bail O. Cited by: Sterne M. Anthrax. In: Stableforth AW, Galloway IA, eds. Infectious Diseases of Animals, Volume I. London, England: Butterworth Scientific Publications; 1959:22.
32. Keppie J, Harris-Smith PW, Smith H. The chemical basis of the virulence of Bacillus anthracis, IX: its aggressins and their mode of action. Br J Exp Pathol. 1963;44:446-453.
33. Mikesell P, Ivins BE, Ristroph JD, Dreier TM. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immunol. 1983;39:371-376.
34. Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immunol. 1985;49:291-297.
35. Uchida I, Sekizaki T, Hashimoto K, Terakado N. Association of the encapsulation of Bacillus anthracis with a 60-megadalton plasmid. J Gen Microbiol. 1985;131:363-367.
36. Longfield R. Anthrax. In: Strickland GT, ed. Hunter's Tropical Medicine. 7th ed. Philadelphia, Pa: WB Saunders Co; 1991:434-438.
37. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol. 1957;73:485-494.
38. Fritz DL, Jaax NK, Lawrence WB, et al. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest. 1995;73:691-702.
39. Dahlgren CM, Buchanan LM, Decker HM, Freed SW, Phillips CR, Brachman PS. Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg. 1960;72:24-31.
40. Carr EA, Rew R. Recovery of Bacillus anthracis from the nose and throat of apparently healthy workers. J Infect Dis. 1957;100:169-171.
41. Watson A, Keir D. Information on which to base assessments of risk from environments contaminated with anthrax spores. Epidemiol Infect. 1994; 113:479-490.
42. Gleiser CA, Berdjis CC, Hartman HA, Gochenour WS. Pathology of experimental respiratory anthrax in Macaca mulatta. Br J Exp Pathol. 1963; 44:416-426.
43. Gold H. Anthrax: a report of 117 cases. Arch Intern Med. 1955;96:387-396.
44. Brachman PS. Anthrax. In: Hoeprich PD, Jordan MC, Ronald AR, eds. Infectious Diseases. 5th ed. Philadelphia, Pa: JB Lippincott Co; 1994:1003-1008.
45. Sirisanthana T, Navachareon N, Tharavichitkul P, Sirisanthana V, Brown AE. Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis. Am J Trop Med Hyg. 1984;33:144-150.
46. Sirisanthana T, Nelson KE, Ezell JW, Abshire TG. Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Am J Trop Med Hyg. 1988;39:575-581.
47. Levy LM, Baker N, Meyer MP, Crosland P, Hampton J. Anthrax meningitis in Zimbabwe. Cent Afr J Med. 1981;27:101-104.
48. Lightfoot NF, Scott RJD, Turnbull BCB. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull Suppl. 1990;68:95-98.
49. Knudson GB. Treatment of anthrax in man: history and current concepts. Mil Med. 1986;151: 71-77.
50. Turnbull PCB. Anthrax vaccines: past, present, and future. Vaccine. 1991;9:533-539.
51. Shlyakhov EN, Rubenstein E. Human live anthrax vaccine in the former USSR. Vaccine. 1994; 12:727-730.
52. Turnbull PCB, Broster MG, Carman JA, Manchee RJ, Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immunol. 1986;52:356-363.
53. Turnbull PCB, Leppla SH, Broster MG, Quinn CP, Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol. 1988;177: 293-303.
54. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. Am J Public Health. 1962;52: 632-645.
55. Anthrax vaccine adsorbed [package insert]. Lansing: Michigan Dept of Public Health; 1987.
56. Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immunol. 1986;52:509-512.
57. Broster MG, Hibbs SE. Protective efficacy of anthrax vaccines against aerosol challenge. Salisbury Med Bull Suppl. 1990;68:91-92.
58. Ivins BE, Fellows PF, Pitt MLM, et al. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med Bull Suppl. 1996;87: 125-126.
59. Pitt MLM, Ivins BE, Estep JE, Farchaus J, Friedlander AM. Comparison of the efficacy of purified protective antigen and MDPH to protect nonhuman primates from inhalational anthrax. Salisbury Med Bull Suppl. 1996;87:130.
60. Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immunol. 1992;60:662-668.
61. Iacono-Connors LC, Welkos SL, Ivins BEW, Dalrymple JM. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect Immunol. 1991;59: 1961-1965.
62. Ivins BE, Welkos SL. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect Immunol. 1986;54:537-542.
63. Ivins BE, Welkos SL, Knudson GB, Little SF. Immunization against anthrax with aromatic compound-dependent (aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect Immunol. 1990;58:303-308.
64. Health Aspects of Chemical and Biological Weapons. Geneva, Switzerland: World Health Organization; 1970.
65. Huxsoll DL, Parrott CD, Patrick WC. Medicine in defense against biological warfare. JAMA. 1989; 262:677-679.
66. Friedlander AM, Welkos SL, Pitt MLM, et al. Post-exposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239-1242.
67. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg. 1956;54:28-36.